Q-omics provides the consensus-scored ZNF705A profile across patient tissues and cancer cell-line models. ZNF705A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF705A is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, ZNF705A RNA expression shows 6,769 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUAD, and TGCT as cancer lineages where ZNF705A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF705A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF705A survival associations across molecular data types. ZNF705A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF705A RNA expression–survival associations across cancer types. High ZNF705A expression shows unfavorable associations in KIRC, KICH, LUSC, THCA and PCPG, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF705A RNA expression.
This table summarizes ZNF705A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF705A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF705A shows lower tumor expression in LUAD, LUSC and KICH and higher tumor expression in KIRC, KIRP and COAD. The LUAD box plot shows higher ZNF705A RNA expression in normal versus tumor tissue (log2 FC = −0.072, t-test p < 0.001).
This table shows molecular features associated with ZNF705A in patient tissues and cancer cell lines. In patient samples, ZNF705A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF705A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
